Aarey Drugs & Pharmaceuticals Limited
Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS) financial statements and selected valuation metrics from NSE/BSE exchange filings through 30 June 2026.
Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals
aareydrugs.com(opens the company website in a new tab)Key metrics
Price as of 2026-09-03
Sign in for full ratios and TTM. Learn about these metrics →
Share price
NSE closing price from historical market data.
Loading price history…
Statement tables · Consolidated
Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.
Amounts in ₹ Cr · NSE preferred when both exchanges report the same period · tap + to expand rows
Quarterly results
Quarterly · ₹ Cr · tap + rows to expand
| Metric | Mar 2025 | Jun 2025 | Sept 2025 |
|---|---|---|---|
| Sales | 108 Cr | 102 Cr | 84 Cr |
| Operating expenses (approx.) | 113 Cr | 101 Cr | 82 Cr |
| EBITDA | -5 Cr | 2 Cr | 3 Cr |
| OPM % | -4.5% | 1.7% | 3.1% |
| Other income | 8 Cr | 2 Cr | 0.79 Cr |
| Interest | 2 Cr | 1 Cr | 1 Cr |
| Depreciation | -1 Cr | 0.49 Cr | 0.69 Cr |
| Profit before tax | 2 Cr | 2 Cr | 1 Cr |
| Tax % | 71.1% | 20.6% | 30.9% |
| Net profit | 0.47 Cr | 1 Cr | 1 Cr |
| EPS (₹) | ₹0.04 | ₹0.48 | ₹0.72 |
Profit & loss (annual)
Annual · last column is TTM · ₹ Cr · tap + to expand
| Metric | Mar 2025 | TTM |
|---|---|---|
| Sales | 474 Cr | Sign in for TTM |
| Operating expenses (approx.) | 472 Cr | Sign in for TTM |
| EBITDA | 2 Cr | Sign in for TTM |
| OPM % | 0.5% | Sign in for TTM |
| Other income | 10 Cr | Sign in for TTM |
| Interest | 4 Cr | Sign in for TTM |
| Depreciation | 2 Cr | Sign in for TTM |
| Profit before tax | 6 Cr | Sign in for TTM |
| Tax % | 34.1% | Sign in for TTM |
| Net profit | 4 Cr | Sign in for TTM |
| EPS (₹) | ₹3.27 | Sign in for TTM |
| Dividend payout % | 0.0% | Sign in for TTM |
Trailing twelve months totals and margin rows
Balance sheet
Annual · ₹ Cr · tap + rows to expand
| Metric | Mar 2025 |
|---|---|
| Equity capital | 28 Cr |
| Reserves | 110 Cr |
| Borrowings | 35 Cr |
| Other liabilities | 65 Cr |
| Total liabilities | 238 Cr |
| Fixed assets (net) | 16 Cr |
| CWIP | 0 Cr |
| Investments | 2 Cr |
| Loans & advances | 30 Cr |
| Inventories | 45 Cr |
| Trade receivables | 130 Cr |
| Cash & bank | 1 Cr |
| Other assets | 13 Cr |
| Total assets | 238 Cr |
Cash flows
Annual · ₹ Cr · tap + rows to expand · last column includes FCF
| Metric | Mar 2025 |
|---|---|
| Cash from operating activity | 10 Cr |
| Cash from investing | -6 Cr |
| Cash from financing | -4 Cr |
| Net cash flow | -0.12 Cr |
| Free cash flow (OCF − Capex) | 10 Cr |
Ratios
Ratios as reported or derived per annual period.
| Metric | Mar 2025 |
|---|---|
| ROCE % | 5.8% |
| ROE % | 2.9% |
| Debtor days | 100 |
| Inventory days | 35 |
| Days payable | 42 |
| Cash conversion cycle | 93 |
| Debt / equity | 0.25 |
| Current ratio | 2.20 |
| Net debt / EBITDA | 14.83 |
Compare with peers
Loading peers…